NZ537920A - An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand - Google Patents

An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand

Info

Publication number
NZ537920A
NZ537920A NZ537920A NZ53792000A NZ537920A NZ 537920 A NZ537920 A NZ 537920A NZ 537920 A NZ537920 A NZ 537920A NZ 53792000 A NZ53792000 A NZ 53792000A NZ 537920 A NZ537920 A NZ 537920A
Authority
NZ
New Zealand
Prior art keywords
ser
leu
val
gly
ala
Prior art date
Application number
NZ537920A
Other languages
English (en)
Inventor
Avi J Ashkenazi
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ537920A publication Critical patent/NZ537920A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ537920A 1999-06-28 2000-06-26 An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand NZ537920A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14134299P 1999-06-28 1999-06-28

Publications (1)

Publication Number Publication Date
NZ537920A true NZ537920A (en) 2006-10-27

Family

ID=22495287

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ515990A NZ515990A (en) 1999-06-28 2000-06-26 Methods for making Apo-2 ligand using divalent metal ions
NZ537920A NZ537920A (en) 1999-06-28 2000-06-26 An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ515990A NZ515990A (en) 1999-06-28 2000-06-26 Methods for making Apo-2 ligand using divalent metal ions

Country Status (12)

Country Link
US (3) US7855066B1 (enExample)
EP (3) EP1194555B1 (enExample)
JP (2) JP5118796B2 (enExample)
KR (1) KR100674528B1 (enExample)
CN (2) CN100526463C (enExample)
AU (3) AU6338200A (enExample)
CA (1) CA2377585A1 (enExample)
ES (1) ES2392392T3 (enExample)
IL (2) IL147029A0 (enExample)
MX (1) MXPA01013236A (enExample)
NZ (2) NZ515990A (enExample)
WO (1) WO2001000832A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
EP1867719A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU6338200A (en) * 1999-06-28 2001-01-31 Genentech Inc. Methods for making apo-2 ligand using divalent metal ions
IL161051A0 (en) * 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
AU2007200478A1 (en) * 2001-11-13 2007-02-22 Genentech, Inc. APO2 ligand/trail formulations
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
JP2005521640A (ja) 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Apo−2リガンド/TRAIL製剤
CA2489348A1 (en) * 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
GB0328261D0 (en) 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
DK1733037T3 (en) 2004-03-11 2015-01-12 Genentech Inc Process for the preparation of polypeptides
MX2007001469A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
WO2006017859A2 (en) 2004-08-06 2006-02-16 Genentech, Inc. Assays and methods using biomarkers
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AU2006279618A1 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
GB0524316D0 (en) * 2005-11-29 2006-01-04 Medical Res Council Tumour necrosis factor-related apoptosis-inducing ligands (TRAILs)
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
CN102775491A (zh) * 2011-05-09 2012-11-14 中国人民解放军第二军医大学 单链化的人凋亡素2配体三聚体蛋白质的制法和用途
CN102443055B (zh) * 2011-10-26 2017-07-28 浙江海正药业股份有限公司 一种重组人肿瘤坏死因子相关凋亡诱导配体的纯化工艺
JP6355425B2 (ja) * 2014-05-20 2018-07-11 キヤノン株式会社 システムおよびその制御方法
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2017161173A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc. Engineered trail for cancer therapy
CN111320384A (zh) * 2019-04-04 2020-06-23 株式会社小原 光学玻璃的制造方法
JP7429622B2 (ja) * 2020-08-26 2024-02-08 株式会社オハラ 光学ガラスの製造方法
CN115980241B (zh) * 2023-02-11 2025-01-07 烟台新特路新材料科技有限公司 一种硫代酯类抗氧化剂含量的检测方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
US5169770A (en) 1987-12-21 1992-12-08 The University Of Toledo Agrobacterium mediated transformation of germinating plant seeds
US6063763A (en) * 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
EP0550629A1 (en) 1990-08-17 1993-07-14 Genentech, Inc. Metal ion mediated receptor binding of polypeptide hormones
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992017200A2 (en) 1991-03-28 1992-10-15 Genentech, Inc. Stable growth hormone metal ion formulations
US6387650B1 (en) * 1995-06-07 2002-05-14 Biocontrol Systems, Inc. Method and composition for detecting bacterial contamination in food products
EP1666591B1 (en) * 1995-06-29 2011-03-23 Immunex Corporation Cytokine that induces apoptosis
DE19547933A1 (de) * 1995-12-22 1997-06-26 Boehringer Mannheim Gmbh Multimere Formen von IL-16, Verfahren zu ihrer Herstellung und Verwendung
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2256464A1 (en) 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
AU733380B2 (en) 1996-10-03 2001-05-10 Regents Of The University Of Michigan, The Nucleotide and protein sequence of mammastatin and methods of use
CA2266439C (en) 1996-10-25 2009-06-16 Human Genome Sciences, Inc. Neutrokine .alpha.
CA2274987C (en) 1996-12-23 2012-01-24 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
CA2301847A1 (en) 1997-08-26 1999-03-04 Genentech, Inc. Rtd receptor
US6740739B1 (en) * 1998-01-15 2004-05-25 Genentech, Inc. Substitutional variants of APO-2 ligand
SE9802454D0 (sv) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
AU6338200A (en) * 1999-06-28 2001-01-31 Genentech Inc. Methods for making apo-2 ligand using divalent metal ions
WO2001018055A1 (en) 1999-09-10 2001-03-15 Eli Lilly And Company Flint analog compounds and formulations thereof
AU7053000A (en) 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
IL161051A0 (en) * 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
JP2005521640A (ja) * 2001-11-13 2005-07-21 ジェネンテック・インコーポレーテッド Apo−2リガンド/TRAIL製剤
CN100500841C (zh) * 2005-10-10 2009-06-17 华东理工大学 一种表达可溶性trail蛋白的方法

Also Published As

Publication number Publication date
KR20020016856A (ko) 2002-03-06
AU2005211561B2 (en) 2008-08-21
CN100526463C (zh) 2009-08-12
WO2001000832A1 (en) 2001-01-04
NZ515990A (en) 2003-10-31
CA2377585A1 (en) 2001-01-04
US7855066B1 (en) 2010-12-21
JP2003503057A (ja) 2003-01-28
KR100674528B1 (ko) 2007-01-29
IL147029A (en) 2012-02-29
US20120077740A1 (en) 2012-03-29
EP1194555A1 (en) 2002-04-10
JP5118796B2 (ja) 2013-01-16
CN101633692A (zh) 2010-01-27
AU2005211561A1 (en) 2005-10-13
AU6338200A (en) 2001-01-31
US20070161564A1 (en) 2007-07-12
EP2339003A2 (en) 2011-06-29
ES2392392T3 (es) 2012-12-10
AU2008249162A1 (en) 2008-12-11
EP2339003A3 (en) 2011-10-19
EP1194555B1 (en) 2012-09-26
EP2311956A1 (en) 2011-04-20
JP2011088897A (ja) 2011-05-06
CN1370232A (zh) 2002-09-18
MXPA01013236A (es) 2002-06-21
WO2001000832A9 (en) 2012-03-08
IL147029A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
EP1194555B1 (en) Methods for making apo-2 ligand using divalent metal ions
US20090137476A1 (en) Apo-2 ligand variants and uses thereof
JP4574350B2 (ja) Apo−2リガンド/trail変異体とその使用法
KR101283802B1 (ko) 냉각 결정화를 이용한 apo-2 리간드/trail의 정제방법
AU2011265480A1 (en) Methods for making APO-2 ligand using divalent metal ions
HK1140780A (en) Methods for making apo-2 ligand using divalent metal ions
AU2002330173A1 (en) Apo-2 ligand variants and uses thereof
AU2007201621A1 (en) Apo-2 ligand variants and uses thereof
AU2011235952A1 (en) APO-2 ligand variants and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 26 JUN 2020 BY THOMSON REUTERS

Effective date: 20130514

EXPY Patent expired